StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) company profile

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)

Close on Nov 17, 2026Market cap $15.86BP/E –Yield –

About Charles River Laboratories International

Services-Commercial Physical & Biological Research, SIC 8731

Charles River Laboratories International, Inc. is an early-stage drug development partner offering research models and non-clinical development services. The company organizes its operations across three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Its core offerings include purpose-bred rodents and larger research models, genetically engineered model creation, diagnostic testing, and cellular materials for research and therapies. It also delivers integrated drug discovery, bioanalytical support, safety pharmacology, specialized toxicology, pathology evaluations, and quality control testing such as endotoxin and microbial detection. The company serves global pharmaceutical and biotechnology corporations, academic institutions, contract research organizations, hospitals, and government agencies, along with chemical, consumer product, and medical device manufacturers.

The company operates more than 120 facilities across more than 20 countries, with research model production locations positioned across North America, Europe, and Asia. Charles River Laboratories International, Inc. maintains its corporate headquarters in Wilmington, Massachusetts.

Summary of the business section of Charles River Laboratories International's latest annual report, written by StockData.

Company profile

Company

Legal name
Charles River Laboratories International, Inc.
Founded
1947
Headquarters
Wilmington, MA
Address
251 Ballardvale St 01887
Phone
(781) 222-6000
Website
criver.com
Employees
19,700, Dec 27, 2025
Industry
Services-Commercial Physical & Biological Research
Fiscal year ends
December 27
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
CRL
Exchange
NYSE
IPO date
Jun 26, 2000
Shares outstanding
48M, Jul 25, 2026
Public float
$7.32B, Jun 28, 2025
Filer category
Large accelerated filer
SEC CIK
1100682
CUSIP
159864107
ISIN
US1598641074
FIGI
BBG000BG5BL8
Share class FIGI
BBG001S7Q271
LEI
549300BSQ0R4UZ5KX287
EIN
06-1397316

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Birgit GirshickChief Executive Officer, Director79,288
Michael Gunnar KnellSVP, Finance and CAO11,203
Shannon M. ParisottoCEVP, Disc & Safety Assessment42,997
Glenn ColemanEVP & Chief Financial Officer27,762
Joseph W. LaPlumeEVP, Corp Strategy & Develop31,041
Victoria L. CreamerEVP & Chief People Officer34,230
Mark MintzEVP, Chief Information Officer9,546
Flavia PeaseCorporate Executive VP & CFO17,297
James C. FosterDirector233,410
Nancy C. AndrewsDirector5,402
Steven BargDirector3,287
Paul W. GravesDirector2,384
Craig B. ThompsonDirector3,851
Martin MackayDirector17,137
Virginia M. WilsonDirector6,349
Abraham CeesayDirector2,384
Mark J. EnyedyDirector2,384
George Llado Sr.Director6,702
Reshema Kemps-PolancoDirector4,563
George MassaroDirector5,575

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$15.44M$24.91M$3.56M$81$148
FY2024$13.47M$3.10M$3.50M$74$129
FY2023$14.10M$20.47M$3.69M$94$126
FY2022$13.45M$10.66M$3.30M$87$124
FY2021$13.71M$41.20M$4.39M$147$126
FY2020$13.48M$50.02M$2.77M$166$113

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
James C. Foster
Chair, President, Chief Executive Officer and Director
$1.55M–$11.60M$2.18M$105.83K$15.44M+15%
Michael G. Knell
Senior Vice President, Chief Accounting Officer & Interim Chief Financial Officer
$448.12K$30.00K$1.20M$347.50K$86.61K$2.11M–
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer
$760.96K–$4.12M$861.80K$152.01K$5.90M+17%
Joseph LaPlume
Corporate Executive Vice President Corporate Development and Strategy
$570.17K–$2.26M$563.61K$119.11K$3.51M+18%
Victoria Creamer
Corporate Executive Vice President, Chief People Officer
$553.75K–$2.11M$547.39K$124.79K$3.33M+19%
Flavia H. Pease
Corporate Executive Vice President, Chief Financial Officer
$507.69K–$2.41M–$35.46K$2.95M-6%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 27, 2025, we had approximately 19,700 employees (including approximately 2,400 science professionals with advanced degrees, including Ph.D.s, D.V.M.s and M.D.s).”

Corporate history

Events identified from SEC filings

See a number that looks wrong?